Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2–5 Years of Age Homozygous for F508del-CFTR : A Phase 2, Open-Label Clinical Trial
Annals of the American Thoracic Society · 01.11.2024 · 21 (11) · 1550-1559
DOI: 10.1513/annalsats.202402-201oc ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Annals of the American Thoracic Society, online erschienen am 01.11.2024. Verfasst von Mirjam Stahl und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine and. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Rationale
Clinical trials show that lumacaftor/ivacaftor (LUM/IVA) treatment has the potential to modify early cystic fibrosis (CF) disease progression in children as young as 2 years of age.
Objectives
To assess the long-term impact of LUM/IVA treatment on CF disease progression in children aged 2–5 years.
Methods
This phase 2 trial had two parts: part 1, a 48-week, randomized, double-blind, placebo-controlled study of LUM/IVA in children aged 2–5 years (previously reported) was followed by a 48-week open-label treatment period in which all children received LUM/IVA (part 2; reported here). Endpoints assessed in part 2 included absolute changes from baseline in chest magnetic resonance imaging (MRI) global score at Week 96; weight-for-age, stature-for-age, and body mass index (BMI)-for-age z-scores at Week 96; lung clearance index based on lung volume turnover required to reach 2.5% of starting N2 concentration (LCI2.5) through Week 96; chest MRI morphological score, chest MRI perfusion score, weight, stature, BMI, and microbiology cultures (oropharyngeal swabs) at Week 96; sweat chloride, amount of immunoreactive trypsinogen, fecal elastase-1 concentration, and fecal calprotectin through Week 96; and number of pulmonary exacerbations, time to first pulmonary exacerbation, and number of CF-related hospitalizations.
Results
Forty-nine children received one or more doses of LUM/IVA in the open-label period (33 in the LUM/IVA to LUM/IVA group and 16 in the placebo to LUM/IVA group), with a mean exposure of 47.1 (standard deviation [SD], 5.2) weeks. The mean absolute change in MRI global score (negative value indicates improvement) from baseline at Week 96 was −2.7 (SD, 7.0; 95% confidence interval [CI], −5.2 to −0.1) in the LUM/IVA to LUM/IVA group and −5.6 (SD, 6.9; 95% CI, −9.2 to −1.9) in the placebo to LUM/IVA group. Improvements in LCI2.5, sweat chloride concentration, and markers of pancreatic function and intestinal inflammation were also observed in both groups. Growth parameters remained stable in both groups. The majority of children had adverse events considered mild (38.8%) or moderate (40.8%). Two (4.1%) children discontinued LUM/IVA treatment because of adverse events (distal intestinal obstruction syndrome [n = 1] and alanine aminotransferase increase [n = 1]).
Conclusions
These findings confirm the potential for early LUM/IVA treatment to alter the trajectory of CF disease progression, including CF lung disease, in children as young as 2 years of age. Clinical trial registered with ClinicalTrials.gov (NCT03625466).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Respiratory Medicine, Immunology, and Critical Care Medicine and.
- German Center for Lung Research (DZL), Associated Partner Site, Berlin, Germany.
- Berlin Institute of Health at Charité-Universitätsmedizin, Berlin, Germany.
- Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany.
- Department of Diagnostic and Interventional Radiology and.
- Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany.
ORCID-Profile: Mirjam Stahl, Felix Doellinger, Anna-Maria Dittrich, Mark O Wielpütz, Marcus A Mall
Zitieren
APA
Stahl, M., Roehmel, J., Eichinger, M., Doellinger, F., Naehrlich, L., Kopp, M. V., Dittrich, A. M., Sommerburg, O., Ray, P., Maniktala, A., Xu, T., Conner, S., Joshi, A., Mascia, M., Wielpütz, M. O., & Mall, M. A. (2024). Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2–5 Years of Age Homozygous for F508del-CFTR : A Phase 2, Open-Label Clinical Trial. Annals of the American Thoracic Society, 21(11), 1550-1559. https://doi.org/10.1513/annalsats.202402-201oc
Vancouver
Stahl M, Roehmel J, Eichinger M, Doellinger F, Naehrlich L, Kopp MV, et al. Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2–5 Years of Age Homozygous for F508del-CFTR : A Phase 2, Open-Label Clinical Trial. Annals of the American Thoracic Society. 2024;21(11):1550-1559. doi:10.1513/annalsats.202402-201oc
BibTeX
@article{Stahl2024,
author = {Stahl, Mirjam and Roehmel, Jobst and Eichinger, Monika and Doellinger, Felix and Naehrlich, Lutz and Kopp, Matthias V and Dittrich, Anna-Maria and Sommerburg, Olaf and Ray, Partha and Maniktala, Anita and Xu, Tu and Conner, Sarah and Joshi, Aniket and Mascia, Molly and Wielpütz, Mark O and Mall, Marcus A},
title = {Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2–5 Years of Age Homozygous for F508del-CFTR : A Phase 2, Open-Label Clinical Trial},
journal = {Annals of the American Thoracic Society},
year = {2024},
volume = {21},
number = {11},
pages = {1550--1559},
doi = {10.1513/annalsats.202402-201oc}
}
EUVIMED